Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, announced a multi-target, integrated drug discovery collaboration with Sitryx Therapeutics, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.
The energetic status of cells has been shown to be pivotal in controlling the behaviour of disease associated cells in immuno-oncology and immuno-inflammation. Correcting immune cell function and/or inhibiting tumour cell growth through targeting metabolic pathways has the potential to deliver new complementary and highly-differentiated approaches to treat a wide range of severe diseases.
Sitryx’s proprietary science is led by a highly-experienced management team, supported by GlaxoSmithKline’s drug discovery experience and world-class academic founders, in addition to Sygnature’s significant expertise in immuno-oncology and immunology drug discovery. Sitryx Therapeutics was founded by six world-leading researchers in the field of immunology and immuno-regulation, including Houman Ashrafian, Luke O’Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum and Paul Peter Tak.
Dr Simon Hirst, CEO and Founder of Sygnature, commented:
“We are pleased to have been selected by Sitryx to support their ground-breaking research efforts to develop disease-modifying therapeutics across multiple biological targets in immuno-oncology and immuno-inflammation. Our considerable in-house knowledge of immuno-oncology and immunology discovery will enable us to efficiently navigate these complex areas of biology to support the identification and optimisation of novel and selective small molecules while developing a deep understanding of their mode-of-action.”
Dr Neil Weir, CEO of Sitryx, said:
“Sygnature Discovery has an established reputation as a provider of premium integrated drug discovery and pre-clinical services and the Sitryx team has an extensive track record of success in the discovery and development of novel drugs. We will combine our considerable know-how and expertise to deliver new, highly-effective disease-modifying therapeutics in immuno-oncology and immuno-inflammation.”
Sygnature Discovery (Nottingham, UK) is a leading independent integrated drug discovery and pre-clinical services company. The company operates fully-enabled research facilities in Nottingham and Alderley Park (UK) housing over 200 research scientists (80% with PhDs). Since 2011, the company delivered 14 drug candidates to its clients which have subsequently entered the clinic (Phases I and II). In 2017, Sygnature Discovery received the prestigious Queen’s Award for Enterprise for International Trade.
Sitryx (Oxford, UK) is a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. The company, founded with seed funding from SV Health investors, has raised a total of $30 million in its Series A financing round from a syndicate of specialist international healthcare investors co-led by SV Health Investors and Sofinnova Partners, and also including Longwood Fund and the global healthcare company, GSK.